Adalimumab: Efficacy and safety in psoriasis and rheumatoid arthritis

Dermatologic Therapy

Volumn 17, Issue 5, 2004, Pages 427-431

  Patel, Toral ^a   Gordon, Kenneth B ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Adalimumab; Biologic therapy; Psoriasis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; ANTIRHEUMATIC AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; BACKACHE; BIOLOGICAL THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; COUGHING; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATURIA; HISTOCHEMISTRY; HUMAN; HYPERLIPIDEMIA; HYPERPHOSPHATASEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INJECTION SITE; LOW DRUG DOSE; NAUSEA; PAIN; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SINUSITIS; STATISTICAL SIGNIFICANCE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 6344286067     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04045.x     Document Type: Review

References (14)

1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001: 137: 280-284.
2. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002: 138: 657-663.
3. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004: 140: 218-225.
4. Rau R. Adalimumab (a fully human anti-tumor necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002: 61 (Suppl. 2): ii70-ii73.
5. Abbott Laboratories, North Chicago IL. Adalimumab (Humira) package insert 2004.
6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001: 344: 907-916.
7. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001: 19: 617-635.
8. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003: 49: S112-S117.
9. Chen DM, Gordon KB, Leonardi C, Menter AM. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose ranging trial. J Am Acad Dermatol 2004: 50: S1.
10. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003: 48: 35-45.
11. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human and tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003: 30: 2563-2571.
12. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003: 3: 148-155.
13. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996: 32A: 1753-1757.
14. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998: 317: 180-181.